The Lupus Research Alliance seeks to fund biomedical research that will discover better diagnostics, improve medical treatments and advance translational and clinical research that will ultimately lead to a cure for lupus. The three grant mechanisms of the organization, Distinguished Innovator Award, Target Identification in Lupus and Novel Research Grant, provide distinct opportunities for researchers to test their most innovative hypothesis by applying cutting edge methodologies to further investigation in the lupus and autoimmune space.
The Distinguished Innovator Award grant mechanism is intended to attract exceptionally creative scientists from all relevant scientific disciplines and to provide them with a robust and sustained support to explore bold and paradigm shifting ideas that could lead to ground-breaking discoveries in lupus research. Research conducted under this grant mechanism is expected to be highly innovative and to address the fundamental causes of systemic lupus erythematosus that can provide new directions towards a cure.
Click here for the Request for Applications. Please send any scientific inquiries to Dr. Teodora Staeva, Research Director at tstaeva@lupusresearch.org; all administrative inquiries should be sent to Cindy Liriano, Research Department Assistant at cliriano@lupusresearch.org.
To submit an Application, please visit proposalCentral at http://proposalcentral.altum.com/ and search for the Lupus Research Alliance Grant Application. All Letters of Intent must be received by 11:59 PM ET on March 15, 2019.
Target Identification in Lupus (TIL): up to $200,000/year total costs for up to 3 years.
Supports highly meritorious research focused on the identification and scientific and/or clinical investigation of molecular pathways and therapeutic targets that will lead to new therapies or improved management for patients with lupus.
Click here for the Request for Applications. Please send any scientific inquiries to Dr. Teodora Staeva, Research Director at tstaeva@lupusresearch.org; all administrative inquiries should be sent to Cindy Liriano, Research Department Assistant at cliriano@lupusresearch.org.
To submit an Application, please visit proposalCentral at http://proposalcentral.altum.com/ and search for the Lupus Research Alliance Grant Application. The earliest submission date is October 15, 2018 and all applications must be received by 5:00 PM ET on February 1, 2019.
Please note that while the Target Identification in Lupus and the Novel Research Grants funding mechanisms follow the same review timeline, they have distinct objectives, application templates, and selection criteria. The same research project may not be submitted for consideration to both grant mechanisms. Such submissions will be triaged without review.
Novel Research Grants (NRG): up to $150,000/year total costs for up to 2 years.
Provides early stage support for highly innovative approaches to major challenges in lupus research. Special emphasis is placed on lupus studies exploring fundamental mechanisms, novel targets and pathways, novel technologies, and interdisciplinary approaches. Early-career investigators are encouraged to apply through this mechanism.
Click here for the Request for Applications. Please send any scientific inquiries to Dr. Teodora Staeva, Research Director at tstaeva@lupusresearch.org; all administrative inquiries should be sent to Cindy Liriano, Research Department Assistant at cliriano@lupusresearch.org.
To submit an Application, please visit proposalCentral at http://proposalcentral.altum.com/ and search for the Lupus Research Alliance Grant Application. The earliest submission date is October 15, 2018 and all applications must be received by 5:00 PM ET on February 1, 2019.
Please note that while the Novel Research Grants and the Target Identification in Lupus funding mechanisms follow the same review timeline, they have distinct objectives, application templates, and selection criteria. The same research project may not be submitted for consideration to both grant mechanisms. Such submissions will be triaged without review.
Analysis of Lupus Patient-Focused Drug Development Pre-Meeting Survey Data: up to $25,000 for 6 months
This RFP is a collaboration of the Lupus and Allied Diseases Association and the Lupus Research Alliance and is soliciting proposals for a more detailed data analysis of the Lupus Externally-led Patient-Focused Drug Development (PFDD) Meeting pre-meeting survey. The intent of the analysis is to further the understanding of the perspectives of people with lupus in a way that will help the lupus research community gain insight from the patient data and viewpoint in order to help inform future research, and clinical and regulatory strategies.
Click here for the Request for Proposals. Click here to read Lupus: Patient Voices, the report from the Lupus Externally-led Patient-Focused Drug Development (PFDD) Initiative. Please send any inquiries to Kathleen Arntsen, President & CEO of Lupus and Allied Diseases Association at kathleen@ladainc.org or Diane Gross, National Director of Advocacy and Programs of the Lupus Research Alliance at dgross@lupusresearch.org.
To submit an Application, please visit proposalCentral at http://proposalcentral.altum.com/ and search for the Lupus Research Alliance Grant Application. A Letter of Intent is required and is due by December 14, 2018. All applications must be received by 5:00 PM ET on January 31, 2019.
The purpose of the LuCIN Investigator Initiated Clinical Trial (IICT) grant is to provide support to one or more well justified investigator initiated clinical trial (not fully funded by industry or other sources). It is designed to determine whether, and to what extent, promising new therapies can improve the lives of lupus patients. A primary focus is the evaluation of drugs that are currently approved for other indications and are available for use, known as drug repurposing, which has been a major focus of the Lupus Research Alliance’s interest in drug development for lupus. The intention of this program is to eliminate the barriers that typically hinder lupus clinical trials, ensuring that scientifically-sound treatment approaches are tested in lupus patients as quickly as possible.
Currently, we are not accepting any applications for this grant mechanism. However, we encourage you to contact us if you are interested in receiving future requests for proposals.
Please contact Anisha Viswanathan at aviswanathan@lupusresearch.org if you would like additional information or have any questions about this grant.
